• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Nuro achieves communication in locked-in patient with its neurotechnology

Nuro achieves communication in locked-in patient with its neurotechnology

October 5, 2023 By Sean Whooley

Nuro model of the NUOS Extreme 2 communication system
A model of the NUOS Extreme 2 eyewear with neurological sensors. [Image from the Nuro website]
Nuro announced that a teenager with amyotrophic lateral sclerosis (ALS) regained some communication ability with its technology.

The fully locked-in patient, referred to as “J,” is completely incapacitated by the debilitating disease. Using the company’s NUOS Extreme 2 system, the 17-year-old girl from Chicago controlled critical communication, music and video content. She achieved this using thought control, without any surgery, training or calibration.

Previous efforts saw attempts to assist J with a number of tools. At first, she had the ability to communicate with an eye gaze system. However, that technology became unreliable and ultimately failed, Nuro said in a news release.

The Waterloo, Ontario, Canada-based surgery-free neurotechnology developer then provided the first implementation of NUOS Extreme 2. This enabled the girl to instantly regain her ability to control those communication avenues.

NUOS platform provides neurologically-based communication in a lightweight, smartphone- or tablet-based mobile solution. The advanced mobile version of Nuro’s architecture allows users to communicate using precisely monitored neurological signals. They can do so instantly, without surgery.

The all-in-one platform sets lightweight neurological sensors on Nuro’s ultralight headband and designer glasses with custom software and free support and updates. Nuro offers it as an alternative to eye gaze systems or invasive neurosurgical procedures to retrieve communication in people suffering from neurological diseases, complex disorders, stroke or even traumatic injuries or infections.

“The world should know what has been achieved,” said Francois Grand, founder and CEO of Nuro. “We are absolutely thrilled to assist ‘J’ with the retrieval of her communication despite her critical condition, and this is once again an incredible demonstration and clinical validation of our surgery-free architecture with some of the most advanced states of incapacitation.”

Filed Under: Featured, Health Technology, Neurological, News Well, Software / IT Tagged With: Nuro

More recent news

  • Steris inks $2.1B deal for operating room supplier Xodus Medical
  • Insulet’s Omnipod Discover data platform begins full US rollout
  • Siemens Healthineers exits general ultrasound to focus on cardiac imaging
  • Johnson & Johnson MedTech sets mid-2027 target for ortho spinoff, as Q3 device sales disappoint
  • Olympus receives FDA warning letter after international inspections

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy